Obesity is a major public health problem, predisposing subjects to
metabolic syndrome,
type 2 diabetes, and
cardiovascular diseases. Specific prolyl 4-hydroxylases (P4Hs) regulate the stability of the
hypoxia-inducible factor (HIF), a potent governor of metabolism, with
isoenzyme 2 being the main regulator. We investigated whether HIF-P4H-2 inhibition could be used to treat
obesity and its consequences. Hif-p4h-2-deficient mice, whether fed normal chow or a high-fat diet, had less adipose tissue, smaller adipocytes, and less adipose tissue
inflammation than their littermates. They also had improved
glucose tolerance and
insulin sensitivity. Furthermore, the
mRNA levels of the HIF-1 targets
glucose transporters, glycolytic
enzymes, and
pyruvate dehydrogenase kinase-1 were increased in their tissues, whereas
acetyl-CoA concentration was decreased. The hepatic
mRNA level of the HIF-2 target
insulin receptor substrate-2 was higher, whereas that of two key
enzymes of
fatty acid synthesis was lower. Serum
cholesterol levels and de novo
lipid synthesis were decreased, and the mice were protected against hepatic steatosis.
Oral administration of an HIF-P4H inhibitor,
FG-4497, to wild-type mice with metabolic dysfunction phenocopied these beneficial effects. HIF-P4H-2 inhibition may be a novel
therapy that not only protects against the development of
obesity and its consequences but also reverses these conditions.